Eluxadoline Efficacy in IBS-D Patients Who Report Prior Loperamide Use

American Journal of Gastroenterology

Volumn 112, Issue 6, 2017, Pages 924-932

  Lacy, Brian E ^a   Chey, William D ^b   Cash, Brooks D ^c   Lembo, Anthony J ^d   Dove, Leonard S ^e   Covington, Paul S ^e  

^a DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c UNIVERSITY OF SOUTH ALABAMA   (United States)

^d BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^e ALLERGAN PLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ELUXADOLINE; LOPERAMIDE; PLACEBO; ANTIDIARRHEAL AGENT; GASTROINTESTINAL AGENT; IMIDAZOLE DERIVATIVE; PHENYLALANINE;

ABDOMINAL DISTENSION; ADULT; ARTICLE; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG USE; FEMALE; FLATULENCE; HEADACHE; HUMAN; IRRITABLE COLON; LOWER ABDOMINAL PAIN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT RESPONSE; UPPER ABDOMINAL PAIN; VOMITING; ABDOMINAL PAIN; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; COMPLICATION; IRRITABLE BOWEL SYNDROME; MIDDLE AGED; PAIN MEASUREMENT; SYMPTOM ASSESSMENT;

ABDOMINAL PAIN; ADULT; ANTIDIARRHEALS; DIARRHEA; DOUBLE-BLIND METHOD; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; IMIDAZOLES; IRRITABLE BOWEL SYNDROME; LOPERAMIDE; MALE; MIDDLE AGED; PAIN MEASUREMENT; PHENYLALANINE; SYMPTOM ASSESSMENT;

EID: 85017653669     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2017.72     Document Type: Article

References (23)

1. Longstreth GF, Thompson WG, Chey WD et al. Functional bowel disorders. Gastroenterology 2006; 130: 1480-91.
2. Chey WD, Kurlander J, Eswaran S. Irritable bowel syndrome: a clinical review. JAMA 2015; 313: 949-58.
3. Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol 2012; 10: 712-21.
4. Gralnek IM, Hays RD, Kilbourne A et al. The impact of irritable bowel syndrome on health-related quality of life. Gastroenterology 2000; 119: 654-60.
5. Hulisz D. The burden of illness of irritable bowel syndrome: current challenges and hope for the future. J Manag Care Pharm 2004; 10: 299-309.
6. Paré P, Gray J, Lam S et al. Health-related quality of life, work productivity, and health care resource utilization of subjects with irritable bowel syndrome: baseline results from LOGIC (Longitudinal Outcomes Study of Gastrointestinal Symptoms in Canada), a naturalistic study. Clin Ther 2006; 28: 1726-35.
7. Drossman DA. Functional gastrointestinal disorders: history, pathophysiology, clinical features, and Rome IV. Gastroenterology 2016; 150: 1262-79, e2.
8. Giagnoni G, Casiraghi L, Senini R et al. Loperamide: evidence of interaction with mu and delta opioid receptors. Life Sci 1983; 33 (Suppl 1): 8.
9. Ruppin H. Review: loperamide-a potent antidiarrhoeal drug with actions along the alimentary tract. Aliment Pharmacol Ther 1987; 1: 179-90.
10. Chang L, Lembo A, Sultan S. American Gastroenterological Association Institute technical review on the pharmacological management of irritable bowel syndrome. Gastroenterology 2014; 147: 1149-72.
11. Ford AC, Moayyedi P, Lacy BE et al. American College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation. Am J Gastroenterol 2014; 109 (Suppl 1): S2-S26.
12. Cann PA, Read NW, Holdsworth CD et al. Role of loperamide and placebo in management of irritable bowel syndrome (IBS). Dig Dis Sci 1984; 29: 239-47.
13. US Food and Drug Administration. Lotronex. Highlights of prescribing information. Available at http://www.accessdata.fda.gov/drugsatfda-docs/ label/2010/021107s016lbl.pdf. 2010. Accessed 5 May 2015.
14. Pimentel M, Lembo A, Chey WD et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med 2011; 364: 22-32.
15. Lembo A, Pimentel M, Rao SS. Effi cacy and safety of repeat treatment with rifaximin for diarrhea-predominant irritable bowel syndrome: results of the TARGET-3 study. American College of Gastroenterology Annual Scientifi c Meeting, Philadelphia, PA, USA, 17.22 October 2014.
16. Wade PR, Palmer JM, McKenney S et al. Modulation of gastrointestinal function by MuDelta, a mixed opioid receptor agonist/ opioid receptor antagonist. Br J Pharmacol 2012; 167: 1111-25.
17. US Food and Drug Administration. Viberzi. Highlights of prescribing information. Available at http://www.accessdata.fda.gov/drugsatfda-docs/ label/2015/206940s000lbl.pdf. 2015. Accessed 5 October 2016.
18. Lembo AJ, Lacy BE, Zuckerman MJ et al. Eluxadoline for irritable bowel syndrome with diarrhea. N Engl J Med 2016; 374: 242-53.
19. Hovdenak N. Loperamide treatment of the irritable bowel syndrome. Scand J Gastroenterol Suppl 1987; 130: 81-4.
20. Efskind PS, Bernklev T, Vatn MH. A double-blind placebo-controlled trial with loperamide in irritable bowel syndrome. Scand J Gastroenterol 1996; 31: 463-8.
21. Olafsdottir LB, Gudjonsson H, Jonsdottir HH et al. Irritable bowel syndrome: physicians' awareness and patients' experience. World J Gastroenterol 2012; 18: 3715-20.
22. Lavo B, Stenstam M, Nielsen AL. Loperamide in treatment of irritable bowel syndrome-a double-blind placebo controlled study. Scand J Gastroenterol 1987; 22: 77-80.
23. US Food and Drug Administration. Guidance for Industry-Irritable Bowel Syndrome-Clinical Evaluation of Drugs for Treatment. Available at http://www.fda.gov/downloads/Drugs/.../Guidances/UCM205269.pdf. 2012. Accessed on 30 September 2016.